{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:28:01Z","timestamp":1787120881591,"version":"build-2736575974"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Microdosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing protocols and preparations, adverse events, and competing interests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023428107). Studies of adults microdosing psilocybin MM or truffles were eligible. Risk of bias was assessed across included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven articles (five quantitative and six qualitative studies) met inclusion criteria. Studies were conducted in the United States (n=4), Netherlands, Argentina, and internationally (n=2 each), and Slovenia (n=1) with a total sample of 3,262 adults. Some studies reported microdosing psilocybin MM or truffles may improve well-being, mental health, cognition, physical health, creativity, relationships, pain, curiosity, and substance dependence, and enhance senses among adults. However, the majority of evidence had at least some concerns for risk of bias or was qualitative and used a variety of self-reported outcome measures. Approximately 86% of microdoser motivations were non-medical and only 14% were related to medical diagnoses, mostly for mental health improvements. Extreme heterogeneity was identified across dosing protocols and preparations. The majority of studies did not report adverse events but for those reported, they were mostly mild. All but four studies declared no conflicts of interest and four did not disclose funding sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The certainty of the evidence is low, and a causal effect of microdosing cannot be inferred. Future research should prioritize well-powered randomized controlled trials with standardized and substance-specific dosing protocols to determine causal relationships between microdosing MM or truffles and health outcomes. Mandatory reporting of adverse events and funding sources should be implemented to build the safety profile of microdosing MM and truffles and ensure transparency for potential conflicts of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sytematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42023428107.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1866881","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:05Z","timestamp":1787118485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing"],"prefix":"10.3389","volume":"17","author":[{"given":"Jeni","family":"Page","sequence":"first","affiliation":[{"name":"School of Nursing, Texas Tech University Health Sciences Center","place":["Lubbock, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Moore","sequence":"additional","affiliation":[{"name":"Cook Children\u2019s Medical Center","place":["Fort Worth, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget E.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"School of Nursing, Research Innovation and Scientific Excellence Center, University of Texas Medical Branch","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0J.","family":"Lyons","sequence":"additional","affiliation":[{"name":"The University of Texas Medical Branch at Galveston School of Health Professions","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"The University of Texas Medical Branch at Galveston School of Nursing","place":["Galveston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.forsciint.2003.08.009","article-title":"Morphological and chemical analysis of magic mushrooms in Japan","volume":"138","author":"Tsujikawa","year":"2003","journal-title":"Forensic Sci Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1400","article-title":"Magic truffles or Philosopher's stones: a legal way to sell psilocybin","volume":"5","author":"Pellegrini","year":"2013","journal-title":"Drug Test Anal"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120882","article-title":"Breaking the chains of depression: a systematic review and meta-analysis of psilocybin therapy","volume":"397","author":"Khan","year":"2026","journal-title":"J Affect Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06788-w","article-title":"Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs","volume":"242","author":"Borgogna","year":"2025","journal-title":"Psychopharmacol (Berl)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/02698811241312866","article-title":"Catalyst for change: psilocybin's antidepressant mechanisms-a systematic review","volume":"39","author":"Liebnau","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1416420","article-title":"Psilocybin for major depressive disorder: a systematic review of randomized controlled studies","volume":"15","author":"Li","year":"2024","journal-title":"Front Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/13803395.2024.2363343","article-title":"The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review","volume":"46","author":"Ramos","year":"2024","journal-title":"J Clin Exp Neuropsychol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13741","article-title":"Impact of psilocybin on cognitive function: a systematic review","volume":"78","author":"Meshkat","year":"2024","journal-title":"Psychiatry Clin Neurosci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/02791072.2022.2044096","article-title":"The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: a systematic review","volume":"55","author":"Hodge","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B12","volume-title":"The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/13634615221119386","article-title":"Macrodosing to microdosing with psychedelics: clinical, social, and cultural perspectives","volume":"59","author":"Kaypak","year":"2022","journal-title":"Transcult Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.23r03581","article-title":"Modern psychedelic microdosing research on mental health: a systematic review","volume":"26","author":"Lo","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.neubiorev.2020.09.035","article-title":"Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review","volume":"119","author":"Ona","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106493","article-title":"Effects of psychedelic microdosing on cognitive functions: a systematic review and meta-analysis","volume":"180","author":"Pinhas","year":"2026","journal-title":"Neurosci Biobehav Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1020505","article-title":"Lower-dose psycholytic therapy - a neglected approach","volume":"13","author":"Passie","year":"2022","journal-title":"Front Psychiatry"},{"key":"B19","volume-title":"The Science of Microdosing Psychedelics","author":"Passie","year":"2019"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106204","article-title":"The effect of psychedelic microdosing on animal behavior: a review with recommendations for the field","volume":"174","author":"Syed","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3736\/jcim20090918","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B25","unstructured":"Covidence Systematic Review Software\n          \n          2023"},{"key":"B26","article-title":"Learning how to dose","volume-title":"Sirius","author":"Elena","year":"2020"},{"key":"B27","article-title":"A comprehensive comparison of psilocybin truffles and psilocybin mushrooms dosing","volume-title":"Inwardbound","author":"Coffey","year":"2025"},{"key":"B28","unstructured":"Finding and learning about side effects (adverse reactions)\n          \n          \n          Silver Spring, MD\n          U.S. Food and Drug Administration"},{"key":"B29","unstructured":"What is a serious adverse event\n          \n          \n          Silver Spring, MD\n          U.S. Food and Drug Administration"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"Glob Adv Health Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"B34","first-page":"2013","article-title":"Cochrane Consumers and Communication Review Group: data synthesis and analysis","author":"Ryan","year":"2013","journal-title":"Cochrane Consumers Comm Rev Group"},{"key":"B35","unstructured":"Openai\n          \n          2026"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5049-7","article-title":"Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting","volume":"235","author":"Prochazkova","year":"2018","journal-title":"Psychopharmacol (Berl)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/523n4","article-title":"Salience, sensemaking, and setting in psilocybin microdosing: methodological lessons and preliminary findings of a mixed method qualitative study","volume":"38","author":"Oblak","year":"2025","journal-title":"Philos Psychol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.53680\/vertex.v35i164.544","article-title":"Psilocybin fungi microdose treatment in major depressive disorder: a case report","volume":"35","author":"Zarankin","year":"2024","journal-title":"Vertex"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/imcrj.s395342","article-title":"The effectiveness of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease: a case study","volume":"16","author":"Kinderlehrer","year":"2023","journal-title":"Int Med Case Rep J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2023.2253538","article-title":"Three cases of reported improvement in microsmia and anosmia following naturalistic use of psilocybin and LSD","volume":"55","author":"Kovacevich","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"key":"B42","article-title":"Self-administration of psilocybin in the setting of treatment-resistant depression","volume":"19","author":"Lyons","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102600","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int J Drug Policy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0269881120953994","article-title":"Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention","volume":"36","author":"Petranker","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/02698811211050556","article-title":"Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study","volume":"36","author":"Marschall","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1039\/c9np00011a","article-title":"Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2","volume":"36","author":"Caesar","year":"2019","journal-title":"Nat Prod Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/add.15842","article-title":"The representation of females in clinical trials for substance use disorder conducted in the United States (2010-19)","volume":"117","author":"Gunn","year":"2022","journal-title":"Addiction"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2011.07.010","article-title":"Hallucinogenic drugs in pre-Columbian Mesoamerican cultures","volume":"30","author":"Carod-Artal","year":"2015","journal-title":"Neurologia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"B51","unstructured":"Drug scheduling\n          \n          \n          Springfield, VA\n          U.S. Drug Enforcement Administration, U.S. Department of Justice\n          \n          2024"},{"key":"B52","article-title":"Psilocybin (Magic mushrooms)","volume-title":"National Institutes of Health","year":""},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.mr000033.pub2","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2024-0866","article-title":"The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication","volume":"47","author":"Koning","year":"2025","journal-title":"Trends Psychiatry Psychother"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1201\/b10191-12","article-title":"Hallucinogenic mushrooms in Mexico: An overview","volume":"62","author":"Guzm\u00e1n","year":"2008","journal-title":"Econ Bot"},{"key":"B56","article-title":"Meta-analysis: pitfalls and hints","volume":"5","author":"Greco","year":"2013","journal-title":"Heart Lung Vessel"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.19325","article-title":"Limitations of meta-analyses of studies with high heterogeneity","volume":"3","author":"Imrey","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B58","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1866881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:07Z","timestamp":1787118487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1866881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":58,"alternative-id":["10.3389\/fpsyt.2026.1866881"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1866881","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1866881"}}